Boyd, Cynthia M.
Shetterly, Susan M.
Powers, John D.
Weffald, Linda A.
Green, Ariel R.
Sheehan, Orla C.
Reeve, Emily
Drace, Melanie L.
Norton, Jonathan D.
Maiyani, Mahesh
Gleason, Kathy S.
Sawyer, Jennifer K.
Maciejewski, Matthew L.
Wolff, Jennifer L.
Kraus, Courtney
Bayliss, Elizabeth A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial
https://doi.org/10.1007/s40266-023-01080-y
Funding for this research was provided by:
National Institute on Aging (R33-AG057289)
National Institute on Aging (R33-AG057289)
Article History
Accepted: 16 October 2023
First Online: 20 November 2023
Declarations
:
: This study was funded by the National Institute on Aging (R33-AG057289). Dr. Maciejewski was also supported by a Research Career Scientist award from the Department of Veterans Affairs (RCS 10-391) and by the Center of Innovation to Accelerate Discovery and Practice Transformation (CIN 13-410) at the Durham VA Health Care System. Dr. Green was also supported by NIA K23 AG054742. Dr. Reeve was supported by a NHMRC-ARC Dementia Research Development Fellowship (GNT1105777) and an NHMRC Investigator Grant (GNT1195460). Drs. Boyd, Bayliss, and Maciejewski are also funded by the US Deprescribing Research Network NIA R24 AG064025. Dr. Bayliss is also funded by the IMPACT Health Care Systems Collaboratory U54AG063546.
: C.M.B. is coauthor of a chapter in Uptodate on multimorbiditiy, E.R. is a coauthor of a chapter in Uptodate on deprescribing. All remaining authors have no conflicts to disclose.
: The datasets generated and/or analyzed during the current study are not publicly available due to the privacy protection policies of Kaiser Permanente. Requests for analytic data sets will be considered in consultation with the Institutional Privacy Officer.
: The Kaiser Permanente Colorado and Johns Hopkins University institutional review boards approved the study.The institutional review boards granted a waiver of individual informed consent for this study.
: Not applicable.
: Not applicable.
: EAB and CMB conceptualized and designed the trial and safety monitoring, obtained funding, wrote the protocol, collected and analyzed data, and co-led the manuscript writing. SMS developed and wrote the analytic plan, JDP contributed substantively to the analytic plan, and MLM provided input on the analytic plan. SMS, JDP, LAW, ARG, OCS, ER, MLD, JDN, MM, KSG, JKS, MLM, JLW, and CK provided input on trial design, collection, and interpretation of study results, and development and execution of the trial safety monitoring plan. MLD, JDN, MM, and LAW managed the study including recruitment, enrollment, and data management. ARG, OCS, and ER did the adjudications. In addition to the specific contributions above, all authors have drafted or substantially revised the manuscript. All authors have approved the submitted version of the manuscript, consent to publication, and have agreed to be accountable for the contents. Authorship of all study publications will follow ICMJE authorship criteria.